Novocure to Host Research and Development Day on Dec. 12, 2016

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that the company will hold a research and development day for analysts and investors on Monday, Dec. 12, 2016, from 1 to 4 p.m. EST in New York City. During the event, we plan to provide analyses from completed clinical trials, including the full 695 patient dataset from …

Novocure Reports Second Quarter 2016 Financial Results and Provides Company Update

Three months ended June 30, ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, today reported financial results for the quarter ended June 30, 2016, highlighting year-over-year growth in prescriptions, active patients and reported revenues. Second quarter 2016 highlights include:     Three months ended June 30, …

NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma

Optune designated as category 2A treatment for newly diagnosed GBM, indicating uniform consensus that the intervention is appropriate ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has recommended Optune as a standard treatment option for newly diagnosed glioblastoma (GBM) in its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) …

Novocure Receives FDA Approval for Second Generation Optune System

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its premarket approval (PMA) supplement application for Novocure’s second generation Optune system. The new smaller, lighter Tumor Treating Fields (TTFields) delivery system is now available to glioblastoma (GBM) patients in the United States. Novocure designed the second generation …